Lorem ipsum dolor sit amet vel scelerisque urna vestibulum aliquet
Nullam ac ligula suscipit tortor semper posuere ante ipsum primis in faucibus.
About company
Who are we and what is our specialty?
We strongly believe that early phase clinical trials can be designed to provide critical proof-of-concept data faster and more cost-efficient. Without compromising on quality, the INFECTA team takes pride in designing fit-for-purpose early phase clinical trials which aim to maximally derisk downstream clinical development.
We provide a wide range of services for the development of vaccines, therapeutics, antivirals and biologics. We use and develop various clinical research methodologies and are global leading experts on the controlled human infection models (CHIMs).
Emerging from the longstanding collaboration between five Dutch University Medical Centers and the Centre for Human Drug Research (CHDR), we have a strong legacy in early phase clinical research programs and a strong scientific orientation, including experience with CHIMs.
Mission and vision
Nullam ac ligula suscipit
In ut consequat lorem, vitae sagittis neque. Aliquam non imperdiet erat. Praesent id ipsum eu erat vestibulum aliquet. Mauris luctus lacus diam. Nullam non sapien pretium, egestas urna nec, pretium lectus. Sed ac justo pulvinar est convallis pellentesque. Vestibulum id varius sem, eu imperdiet augue. Aliquam consectetur magna id metus gravida condimentum. Morbi nibh quam, porta vitae convallis at, pulvinar et nisl. Integer fringilla rhoncus eros id posuere. Morbi suscipit volutpat ipsum, non blandit elit ultricies vel.
Mission
Morbi nibh quam, porta vitae convallis at, pulvinar et nisl. Integer fringilla rhoncus eros id posuere. Morbi suscipit volutpat ipsum, non blandit elit ultricies vel.
Mission
Morbi nibh quam, porta vitae convallis at, pulvinar et nisl. Integer fringilla rhoncus eros id posuere. Morbi suscipit volutpat ipsum, non blandit elit ultricies vel.
Mission
Morbi nibh quam, porta vitae convallis at, pulvinar et nisl. Integer fringilla rhoncus eros id posuere. Morbi suscipit volutpat ipsum, non blandit elit ultricies vel.
Our values
Value
Morbi nibh quam, porta vitae convallis at, pulvinar et nisl. Integer fringilla rhoncus eros id posuere. Morbi suscipit volutpat ipsum, non blandit elit ultricies vel.
Value
Morbi nibh quam, porta vitae convallis at, pulvinar et nisl. Integer fringilla rhoncus eros id posuere. Morbi suscipit volutpat ipsum, non blandit elit ultricies vel.
Value
Morbi nibh quam, porta vitae convallis at, pulvinar et nisl. Integer fringilla rhoncus eros id posuere. Morbi suscipit volutpat ipsum, non blandit elit ultricies vel.
Value
Morbi nibh quam, porta vitae convallis at, pulvinar et nisl. Integer fringilla rhoncus eros id posuere. Morbi suscipit volutpat ipsum, non blandit elit ultricies vel.
Our team
Meet the team
Prof. Dr. Meta Roestenberg
CEO
I’m dedicated to harnessing innovation to reduce costs and expand global access to infectious disease products
Dr. Ingrid de Visser – Kamerling
COO
I’m dedicated to high quality, because advancing infectious disease research enhances global health and improves the quality of lives worldwide
Sophie Watertor
Pandemic Preparedness Strategy Specialist
I’m dedicated to staying connected because building a resilient future requires a community. One that shares research, memes, sourdough starters, and ensures everyone has a fair chance to contribute and thrive.
Cynthia Crul
Project Manager
I’m dedicated to transparency because sharing input and results leads to a more equitable world.
Eveline Ijzelenberg
Management Assistant
I’m dedicated to staying connected because I thrive on building meaningful relationships through creativity and open-mindedness. Together, we create opportunities and forge connections that make a real impact.
Saco de Visser
Advisor
I’m dedicated to innovation, driving the development of affordable vaccines and treatments to ensure access to medicine for those who need it most.
Robert Sauerwein
Advisor
I’m dedicated to high-quality work, helping to accelerate the development of products for particularly vulnerable people to combat major infectious diseases.
Ecosystem
Join our ecosystem
INFECTA is an InFECT-NL company. The InFECT-NL foundation is established by a consortium of the University Medical Centers of Amsterdam, Nijmegen, Leiden and Utrecht. InFECT-NL aims to impact global health by improving accessibility of therapeutics and vaccines for infectious diseases. InFECT-NL provides a hub of expertise that connects both private and public organizations and supports academic and regulatory innovation by encouraging collaboration and knowledge sharing. This active network of collaborators invests in biomarker development and establishes new CHIM models.
Through our shared knowledge and experience we deliver high-quality, patient-focused outcomes.
Ecosystem
Join our ecosystem
INFECTA is an InFECT-NL company. The InFECT-NL foundation is established by a consortium of the University Medical Centers of Amsterdam, Nijmegen, Leiden and Utrecht. InFECT-NL aims to impact global health by improving accessibility of therapeutics and vaccines for infectious diseases. InFECT-NL provides a hub of expertise that connects both private and public organizations and supports academic and regulatory innovation by encouraging collaboration and knowledge sharing. This active network of collaborators invests in biomarker development and establishes new CHIM models.
Through our shared knowledge and experience we deliver high-quality, patient-focused outcomes.
Pandemic Preparedness
In ut consequat lorem, vitae sagittis neque. Aliquam non imperdiet erat. Praesent id ipsum eu erat vestibulum aliquet. Mauris luctus lacus diam. Nullam non sapien pretium, egestas urna nec, pretium lectus. Sed ac justo pulvinar est convallis pellentesque. Vestibulum id varius sem, eu imperdiet augue. Aliquam consectetur magna id metus gravida condimentum. Morbi nibh quam, porta vitae convallis at, pulvinar et nisl. Integer fringilla rhoncus eros id posuere. Morbi suscipit volutpat ipsum, non blandit elit ultricies vel.